Li-Fraumeni syndrome is a cancer predisposition syndrome caused by pathogenic TP53 germline variants; it is associated with a high lifelong cancer risk. We analyzed the German Li-Fraumeni syndrome registry, which contains data on 304 individuals. Cancer phenotypes were correlated with variants grouped according to their ability to transactivate target genes in a yeast assay using a traditional (nonfunctional, partially functional) and a novel (clusters A, B, and C) classification of variants into different groups. Partially functional and cluster B or C variants were enriched in patients who did not meet clinical testing criteria. Time to first malignancy was longer in carriers of partially functional variants (hazard ratio = 0.38, 95% CI = 0.22 to 0.66). Variants grouped within cluster B (hazard ratio = 0.45, 95% CI = 0.28 to 0.71) or C (hazard ratio = 0.34, 95% CI = 0.19 to 0.62) were associated with later cancer onset than NULL variants. These findings can be used to risk-stratify patients and inform care.

Muntnich, L. J., Dutzmann, C. M., Grosshennig, A., Harter, V., Keymling, M., Mastronuzzi, A., Montellier, E., Nees, J., Palmaers, N. E., Penkert, J., Pfister, S. M., Ripperger, T., Schott, S., Silchmuller, F., Hainaut, P., Kratz, C. P., Cancer risk in carriers of TP53 germline variants grouped into different functional categories, <<JNCI CANCER SPECTRUM>>, 2025; 9 (1): 1-5. [doi:10.1093/jncics/pkaf008] [https://hdl.handle.net/10807/328043]

Cancer risk in carriers of TP53 germline variants grouped into different functional categories

Mastronuzzi, Angela
Writing – Original Draft Preparation
;
2025

Abstract

Li-Fraumeni syndrome is a cancer predisposition syndrome caused by pathogenic TP53 germline variants; it is associated with a high lifelong cancer risk. We analyzed the German Li-Fraumeni syndrome registry, which contains data on 304 individuals. Cancer phenotypes were correlated with variants grouped according to their ability to transactivate target genes in a yeast assay using a traditional (nonfunctional, partially functional) and a novel (clusters A, B, and C) classification of variants into different groups. Partially functional and cluster B or C variants were enriched in patients who did not meet clinical testing criteria. Time to first malignancy was longer in carriers of partially functional variants (hazard ratio = 0.38, 95% CI = 0.22 to 0.66). Variants grouped within cluster B (hazard ratio = 0.45, 95% CI = 0.28 to 0.71) or C (hazard ratio = 0.34, 95% CI = 0.19 to 0.62) were associated with later cancer onset than NULL variants. These findings can be used to risk-stratify patients and inform care.
2025
Inglese
Muntnich, L. J., Dutzmann, C. M., Grosshennig, A., Harter, V., Keymling, M., Mastronuzzi, A., Montellier, E., Nees, J., Palmaers, N. E., Penkert, J., Pfister, S. M., Ripperger, T., Schott, S., Silchmuller, F., Hainaut, P., Kratz, C. P., Cancer risk in carriers of TP53 germline variants grouped into different functional categories, <<JNCI CANCER SPECTRUM>>, 2025; 9 (1): 1-5. [doi:10.1093/jncics/pkaf008] [https://hdl.handle.net/10807/328043]
File in questo prodotto:
File Dimensione Formato  
pkaf008.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/328043
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact